de-la-Plaza-San-Frutos Marta, García-García Elisa, Martínez-Pascual Beatriz, Esteban Isabel Mínguez, Domínguez-Balmaseda Diego, Sosa-Reina M Dolores
Faculty of Sport Sciences, Universidad Europea de Madrid, Madrid, Spain.
Research Group on Exercise Therapy and Functional Rehabilitation, Faculty of Sport Sciences, Universidad Europea de Madrid, Madrid, Spain.
Front Med (Lausanne). 2024 Jun 25;11:1338317. doi: 10.3389/fmed.2024.1338317. eCollection 2024.
The vaccines developed against COVID-19 have different modes of action, with a primary focus on the spike protein of the virus. Adverse effects following vaccination have been reported, including local and systemic symptoms. Understanding the potential side effects on the urinary tract after vaccination is of importance. Actively investigating and comprehending the potential impact on the urinary tract, we can enhance public health strategies and pave the way for safer and more effective vaccination programs.
The study was based on an online survey that included the Spanish Version of the Overactive Bladder Symptom Score (OABSS-S); 2,362 men and women replied to the survey. After the application of the exclusion criteria, 1,563 participants were insured. In the context of COVID-19, individuals were questioned regarding several key factors related to their vaccination status and medical history. These factors included the number of vaccine doses received, the specific type of vaccine administered, whether they had previously contracted COVID-19, and the frequency of prior infections, if applicable.
A total of 1,563 (74.7% women and 27.3% men) subjects between the ages of 18 and 45 completed the survey and were included in the final analyses. The most frequently administered vaccine type was Pfizer-BioNTech (42.2%), and most subjects received three doses. The proportion of females who received the AstraZeneca vaccine and do not require to urinate during the night is significantly higher compared to males (59.1% vs. 33.3%; <0.05). The proportion of individuals who urinate five or more times during the night is higher in those who have received a single vaccine dose than in those who have received three doses (2.2% vs. 0.1%; <0.05).
COVID-19 vaccination has been found to impact the lower urinary tract (LUT) and overactive bladder (OAB). Initially, LUT symptoms worsened, and OABSS-S scores increased after the first vaccine dose in individuals under 45 years old. However, symptoms improved after receiving the third and fourth doses. Gender differences were observed in the vaccination effects. Men vaccinated with AstraZeneca reported a higher number of nighttime voids, while women vaccinated with Moderna reported more daytime voids.
针对新冠病毒研发的疫苗具有不同的作用方式，主要聚焦于病毒的刺突蛋白。已报告了接种疫苗后的不良反应，包括局部和全身症状。了解接种疫苗后对尿路的潜在副作用很重要。通过积极调查和理解对尿路的潜在影响，我们可以加强公共卫生策略，并为更安全、更有效的疫苗接种计划铺平道路。
该研究基于一项在线调查，其中包括西班牙文版的膀胱过度活动症症状评分（OABSS-S）；2362名男性和女性回复了该调查。应用排除标准后，有1563名参与者被纳入研究。在新冠疫情背景下，询问了个体与他们的疫苗接种状况和病史相关的几个关键因素。这些因素包括接种的疫苗剂量数、接种的具体疫苗类型、他们是否曾感染过新冠病毒，以及既往感染频率（如适用）。
共有1563名年龄在18至45岁之间的受试者（74.7%为女性，27.3%为男性）完成了调查并被纳入最终分析。最常接种的疫苗类型是辉瑞 - 生物科技公司的疫苗（42.2%），大多数受试者接种了三剂。接种阿斯利康疫苗且夜间无需排尿的女性比例显著高于男性（59.1%对33.3%；<0.05）。接种一剂疫苗的个体夜间排尿五次或更多次的比例高于接种三剂的个体（2.2%对0.1%；<0.05）。
已发现新冠疫苗接种会影响下尿路（LUT）和膀胱过度活动症（OAB）。最初，45岁以下个体在接种第一剂疫苗后，LUT症状恶化，OABSS-S评分增加。然而，在接种第三剂和第四剂后症状有所改善。在疫苗接种效果方面观察到了性别差异。接种阿斯利康疫苗的男性报告夜间排尿次数更多，而接种莫德纳疫苗的女性报告白天排尿次数更多。
